Collecting tumor samples to improve cancer treatment matching
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
This study is collecting tumor samples from patients with advanced cancer to see if analyzing their genes can help doctors find the best treatments for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 7 sites (Hamilton, Ontario and 6 other locations) |
| Trial ID | NCT02906943 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather archival tumor samples from patients with advanced solid tumors to analyze biomarkers that may inform treatment options. By utilizing next-generation sequencing, the study seeks to identify specific molecular characteristics of cancers, which can help physicians determine the most appropriate clinical trials or approved therapies for individual patients. Additionally, the study aims to establish a province-wide registry of genomic data to enhance cancer care across Ontario.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically confirmed advanced solid tumors who are candidates for systemic therapy and have sufficient archived tumor tissue.
Not a fit: Patients who have received more than two lines of prior cytotoxic therapy for their recurrent or metastatic disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with advanced cancers.
How similar studies have performed: Other studies utilizing next-generation sequencing for cancer treatment matching have shown promising results, indicating that this approach is gaining traction in the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with histological confirmation of advanced solid tumor malignancies who are candidates for systemic therapy. 2. All patients must have sufficient FFPE archived tumor tissue for molecular profiling. 3. Patient must be ≥ 18 years old. 4. Patient's ECOG performance status equal to 0 or 1. 5. All patients must have a life expectancy of \> 6 months. 6. All patients must have adequate organ functions. 7. All patients must have signed and dated an informed consent form. Exclusion Criteria: 1\. Patients must not have received more than 2 lines of prior cytotoxic therapy for their recurrent/metastatic disease, with the exception of Phase I trial candidates who will not be excluded if more than 2 lines of prior cytotoxic therapy have been received.
Where this trial is running
Hamilton, Ontario and 6 other locations
- Juravinski Cancer Centre — Hamilton, Ontario, Canada (Active_not_recruiting)
- Kingston General Hospital — Kingston, Ontario, Canada (Active_not_recruiting)
- London Health Sciences Centre — London, Ontario, Canada (Active_not_recruiting)
- The Ottawa Hospital Cancer Centre — Ottawa, Ontario, Canada (Recruiting)
- Princess Margaret Hospital — Toronto, Ontario, Canada (Recruiting)
- Mount Sinai Hospital — Toronto, Ontario, Canada (Active_not_recruiting)
- Sunnybrook Health Sciences Centre — Toronto, Ontario, Canada (Active_not_recruiting)
Study contacts
- Principal investigator: Philippe Bedard, MD — Princess Margaret Hospital, Canada
- Study coordinator: Samanta Del Rossi
- Email: samanta.delrossi@uhn.ca
- Phone: 416-946-4501
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.